Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants

Olena Anoshchenko(Gilead Sciences (United States)), Rita Humeniuk(Gilead Sciences (United States)), Mazin Abdelghany(University of California, San Francisco), Deqing Xiao(Gilead Sciences (United States)), Ran Duan(Taiyuan Maternity and Child Care Hospital), Heng Chen(Gilead Sciences (United States)), Amos Lichtman(Gilead Sciences (United States)), R. Hyland(Gilead Sciences (United States)), Helen Winter(Hackensack University Medical Center), Luzelena Caro(Merck & Co., Inc., Rahway, NJ, USA (United States)), Joe Llewellyn(Gilead Sciences (United States)), Keelin Castellanos(Gilead Sciences (United States)), Lily Mak(Gilead Sciences (United States)), Qin Yue(Gilead Sciences (United States)), Santosh Davies(Gilead Sciences (United States)), Abdul Naveed Shaik(Gilead Sciences (United States)), Chi‐Chi Peng(Gilead Sciences (United States)), Raju Subramanian(Gilead Sciences (United States))
Clinical Pharmacology & Therapeutics
June 28, 2024
Cited by 12


Related Papers